Ensign Peak Advisors
PLRX icon

Ensign Peak Advisors’s Pliant Therapeutics PLRX Stock Holding History

Ensign Peak Advisors’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-42,768
Closed -$563K – 1714
2024
Q4 		$563K Hold
42,768
– – ﹤0.01% 1571
2024
Q3 		$479K Buy
42,768
+7,400
+21% +$92.6K ﹤0.01% 1619
2024
Q2 		$380K Buy
35,368
+9,950
+39% +$128K ﹤0.01% 1658
2024
Q1 		$379K Sell
25,418
-1,282
-5% -$21.1K ﹤0.01% 1667
2023
Q4 		$484K Buy
26,700
+9,250
+53% +$141K ﹤0.01% 1662
2023
Q3 		$303K Buy
17,450
+150
+0.9% +$2.6K ﹤0.01% 1692
2023
Q2 		$313K Buy
+17,300
New +$410K ﹤0.01% 1710

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Ensign Peak Advisors's PLRX Position: Q1 2025 in Review

Ensign Peak Advisors sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 42,768 shares — an estimated $563K sold.

Ensign Peak Advisors first reported a position in PLRX in Q2 2023 and held it in 7 quarters. The position peaked at $563K in Q4 2024. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

  • Ensign Peak Advisors reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ensign Peak Advisors sold 42,768 Pliant Therapeutics shares in Q1 2025, an estimated $563K.
  • Ensign Peak Advisors first reported a position in Pliant Therapeutics in Q2 2023 and held it in 7 quarters.
  • Ensign Peak Advisors's Pliant Therapeutics position peaked at $563K in Q4 2024.
  • 140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on Ensign Peak Advisors's 13F filing for Q1 2025, filed 14 May 2025.